[Skip to Content]
[Skip to Content Landing]
Views 502
Citations 0
Lab, Field, & Clinic
January 8, 2014

New Compound Inhibits Elusive Protein Behind Many Cancers

JAMA. 2014;311(2):127. doi:10.1001/jama.2013.284385

With the ongoing development of targeted therapies, numerous abnormal proteins that play key roles in cancer development and progression have been neutralized by drugs that inhibit their activity. But some, like the Ras family of proteins, have proven difficult to overcome and in some cases have even been considered “undruggable.”

That pessimism appears to be waning, however, in the face of intense interest in cracking Ras proteins’ ability to resist drugs designed to block them. Last June, the National Cancer Institute (NCI) announced that it will devote $10 million to an effort that will bring extramural researchers together to collaborate on new strategies to target RAS oncogenes (http://1.usa.gov/1jGWSQu).